Anti-human immunodeficiency virus activity of novel aminoglycoside- arginine conjugates at early stages of infection

AIDS Research and Human Retroviruses

Volumn 16, Issue 7, 2000, Pages 627-634

  Cabrera, Cecilia ^a   Gutiérrez, Arantxa ^a   Blanco, Julià ^a   Barretina, Jordi ^a   Litovchick, Alexander ^b   Lapidot, Aviva ^b   Evdokimov, Artem G ^b   Clotet, Bonaventura ^a   Esté, José A ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 4 GUANIDINOBUTYRIC ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; ARGININE; CALCIUM ION; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GENTAMICIN C; KANAMYCIN A; MONOCLONAL ANTIBODY; TRANSACTIVATOR PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CALCIUM SIGNALING; CONTROLLED STUDY; CROSS RESISTANCE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG MIXTURE; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS INHIBITION;

ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; ARGININE; CALCIUM SIGNALING; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL SURVIVAL; FLOW CYTOMETRY; HETEROCYCLIC COMPOUNDS; HIV-1; HUMANS; KANAMYCIN; RECEPTORS, CXCR4; VIRUS REPLICATION;

EID: 0034192188     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200308855     Document Type: Article

References (36)

1. 1. Alkhatib G, Broder CC, and Berger EA: Cell type-specific fusion cofactors determine human immunodeficiency virus type 1 tropism for T-cell lines versus primary macrophages. J Virol 1996; 70:5487-5494.
2. 2. Baggiolini M, Dewald B, and Moser B: Human chemokines: An update. Annu Rev Immunol 1997;15:675-705.
3. 3. Cohen J: Exploiting the HIV-chemokine nexus. Science 1997; 275:1261-1264.
4. 4. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, Buser R, Wells TNC, and Proudfoot AE: Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997;276:276-279.
5. 5. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, Meguro K, and Fujino M: A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999;96:5698-5703.
6. 6. Schols D, Struyf S, Van Damme J, Esté JA, Henson G, and De Clercq E: Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997;186:1383-1388.
7. 7. Schols D, Esté JA, Henson G, and De Clercq E: Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res 1997;35:147-156.
8. 8. Donzella GA, Schols D, Lin SW, Esté JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De Clercq E, and Moore JP: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nature Med 1998;4:72-77.
9. 9. Esté JA, Cabrera C, De Clercq E, Struyf S, Van Damme J, Bridger G, Skerlj RT, Abrams MJ, Henson G, Gutierrez A, Clotet B, and Schols D: Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor. Mol Pharmacol 1999;55:67-73.
10. 10. Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, Daar ES, Doms RW, and O'Brien WA: A small-molecule inhibitor director against the chemokine receptor CXCR 4 prevents its use as an HIV-1 coreceptor. J Exp Med 1997;186:1395-1400.
11. 11. Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H, Yoshida N, Waki M, Matsumoto A, Yoshie O, Kishimoto T, Yamamoto N, and Nagasawa T: A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 1997;186:1389-1393.
12. 12. Arakaki R, Tamamura H, Premanathan M, Kanbara K, Ramanan S, Mochizuki K, Baba M, Fujii N, and Nakashima H: T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J Virol 1999;73:1719-1723.
13. 13. Litovchick A, Evdokimov AG, and Lapidot A: Arginine-aminoglycoside conjugates that bind to HIV transactivation response element RNA in vitro. FEBS Lett 1999;445:73-79.
14. 14. Lapidot A, Litovchick A, and Evdokimov AG: Israeli Patent 127773, 1998.
15. 15. Litovchick A, Evdokimov AG, and Lapidot A: Aminoglycoside-arginine conjugates that bind TAR RNA: Synthesis, characterization and antiviral activity. Biochemistry 2000 (in press).
16. 16. O'Brien WA, Sumner-Smith M, Mao SH, Sadeghi S, Zhao JQ, and Chen IS: Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions. J Virol 1996;70:2825-2831.
17. 17. Charneau P, Mirambeau G, Roux P, Paulous S, Buc H, and Clavel F: HIV-1 reverse transcription: A termination step at the center of the genome. J Mol Biol 1994;241:651-662.
18. 18. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J, and De Clercq E: Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988;20:309-321.
19. 19. Esté JA, Witvrouw M, Tu J, Desmyter J, De Clercq E, and Vandamme AM: Inhibition of HIV type 1 Tat-mediated trans-activation by oncostatin M in HLtat cells. AIDS Res Hum Retroviruses 1995;11:1355-1358.
20. 20. Blanco J, Cabrera C, Jou A, Ruiz L, Clotet B, and Esté JA: Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy. AIDS 1999;13:547-555.
21. 21. Valenzuela A, Blanco J, Krust B, Franco R, and Hovanessian AG: Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells. J Virol 1997;71:8289-8298.
22. 22. Esté JA, Schols D, De Vreese K, Van Laethem K, Vandamme AM, Desmyter J, and De Clercq E: Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Mol Pharmacol 1997;52:98-104.
23. 23. Labrosse B, Brelot A, Heveker N, Sol N, Schols D, De Clercq E, and Alizon M: Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol 1998;72:6381-6388.
24. 24. Callebaut C, Blanco J, Benkirane N, Krust B, Jacotot E, Guichard G, Seddiki N, Svab J, Dam E, Muller S, Briand JP, and Hovanessian AG: Identification of V3 loop-binding proteins as potential receptors implicated in the binding of HIV particles to CD(+) cells. J Biol Chem 1998;273:21988-21997.
25. 2N)PR]-TASP inhibits HIV infection in primary macrophage cultures. AIDS Res Hum Retroviruses 1999;15:381-390.
26. 26. Pal R, Mumbauer S, Hoke G, Larocca R, Myers C, Sarngadharen MG, and Stein CA: Effect of Evans blue and trypan blue on syncytium formation and infectivity of human immunodeficiency virus type I and type II in vitro. AIDS Res Hum Retroviruses 1991; 7:537-543.
27. 27. de Vreese K, Kofler-Mongold V, Leutgeb C, Weber V, Vermeire K, Schacht S, Anne J, de Clercq E, Datema R, and Werner G: The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J Virol 1996;70:689-696.
28. 28. Esté JA, De Vreese K, Witvrouw M, Schmit JC, Vandamme AM, Anne J, Desmyter J, Henson GW, Bridger G, and De Clercq E: Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1. Antiviral Res 1996;29:297-307.
29. 29. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura Y, Matsushima K, Yoshida N, Nishikawa S, Kishimoto T, and Nagasawa T: The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature (London) 1998;393:591-594.
30. 30. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, and Littman DR: Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature (London) 1998;393:595-599.
31. 31. Penn ML, Grivel JC, Schramm B, Goldsmith MA, and Margolis L: CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue. Proc Natl Acad Sci USA 1999;96:663-668.
32. 32. Glushakova S, Grivel JC, Fitzgerald W, Sylwester A, Zimmerberg J, and Margolis LB: Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency. Nature Med 1998; 4:346-349.
33. 33. Glushakova S, Yi Y, Grivel JC, Singh A, Schols D, De Clercq E, Collman RG, and Margolis L: Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo. J Clin Invest 1999;104:R7-R11.
34. 34. Esté JA, Cabrera C, Blanco J, Gutierrez A, Bridger G, Henson G, Clotet B, Schols D, and De Clercq E: Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J Virol 1999;73:5577-5585.
35. 35. Blanco J, Jacotot E, Cabrera C, Cardona A, Clotet B, De Clercq E, and Esté JA: The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling. AIDS 1999;13:909-917.
36. 36. Blanco J, Barretina J, Clotet B, Bridger G, Henson G, De Clercq E, and Esté JA: The CXCR4 antagonist AMD3100 efficiently inhibits HIV-1 envelope-induced apoptosis Antimicrob Agents Chemother 2000;44:51-56.